A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
about
Rituximab use in adult primary glomerulopathy: where is the evidence?[Safety and efficacy of off-label use of biologic therapies in patients with inflammatory rheumatic diseases refractory to standard of care therapy : Data from a nationwide German registry (GRAID2)].B Cells, Antibodies, and More.Treatment with rituximab in idiopathic membranous nephropathy.Hurdles to the introduction of new therapies for immune-mediated kidney diseases.Membranous nephropathy: thinking through the therapeutic options.Biologics for the treatment of autoimmune renal diseases.Recent Treatment Advances and New Trials in Adult Nephrotic Syndrome.Treatment of membranous nephropathy: time for a paradigm shift.Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.Low-dose rituximab is poorly effective in patients with primary membranous nephropathy.Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.Long-term outcomes of initial therapy for idiopathic membranous nephropathy.Membranous Nephropathy and Anti-Podocytes Antibodies: Implications for the Diagnostic Workup and Disease Management.Rituximab as a front-line therapy for adult-onset minimal change disease with nephrotic syndrome.
P2860
Q28075564-8B7B205E-BD44-49DC-9AB7-A1D80EAAE9F7Q36394613-606B4694-3C05-47E0-BAAD-1204322FE70DQ36432935-5A4E97C2-EA52-4F30-B9BE-FD9385E0128DQ37511019-F0D57B35-7757-4905-BB36-DE0349F20A84Q38709517-0C91ACCF-30F0-4C32-827C-125D74F9226EQ38733002-06C57DAD-B441-489A-ACCE-4AD610D66F28Q38763327-C6BBA3E5-7E75-4BA9-BB36-6DE0A66B889BQ39335899-03ACAF1D-7660-4812-8022-E16A4DAEAF97Q39410091-459DED11-D3EA-4976-AE22-472A897B7194Q40208466-1C42F471-232C-4B3B-9182-360F1C937076Q40663445-D1947FA5-1BC6-465D-9075-5B5CAB6AA38EQ41073990-74F2395F-9BDD-452C-A248-7632F0EEFCD2Q51246368-58CDC39F-0EA2-48C2-BF97-B8C95D2E5354Q52670774-D5E0164C-A550-4B0E-AF79-57F3FE4A6F99Q55508861-AC6F3568-16DA-4178-8C38-9AF600DAE644
P2860
A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
A Multicenter Randomized Contr ...... mbranous Nephropathy (MENTOR).
@en
A Multicenter Randomized Contr ...... opathic Membranous Nephropathy
@nl
type
label
A Multicenter Randomized Contr ...... mbranous Nephropathy (MENTOR).
@en
A Multicenter Randomized Contr ...... opathic Membranous Nephropathy
@nl
prefLabel
A Multicenter Randomized Contr ...... mbranous Nephropathy (MENTOR).
@en
A Multicenter Randomized Contr ...... opathic Membranous Nephropathy
@nl
P2093
P50
P356
P1433
P1476
A Multicenter Randomized Contr ...... mbranous Nephropathy (MENTOR).
@en
P2093
Alfonso Eirin
Amy N Sussman
Brad H Rovin
Dana V Rizk
Daniel C Cattran
David Philibert
Debbie S Gipson
Dollie F Green
Eddie L Greene
Ellen T McCarthy
P304
P356
10.1159/000430849
P577
2015-06-12T00:00:00Z